UNSPSC 51142412: Eletriptan

This classification denotes a serotonin agonist with the molecular formula C22H26N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 22QOO9B8KI, chemically known as 1h-indole, 3-(((2r)-1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)ethyl)- but generally known as eletriptan, which bears US NIH Compound Identifier 77993. European Medicines Agency schedules Eletriptan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06482MIG.

UNSPSC 51142412 Eletriptan is a Commodity code, but recent state and local procurement activity under this code does not reflect the eletriptan-specific pharmaceutical product the code nominally describes. Instead, issuing bodies are soliciting broader pharmaceutical procurement — naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals through cooperative purchasing arrangements. The actual buying reflects state health departments, county health agencies, and multistate cooperative purchasing alliances acquiring bulk pharmaceutical inventory, specialized medical products, and prescription fulfillment services rather than a single active pharmaceutical ingredient. Issuing bodies include Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration.

Recent opportunities span Florida, Texas, and the multistate MMCAP membership (including Oregon). Seminole County released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida, with a bid deadline of July 26, 2023. The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, representing exploratory market intelligence rather than a committed procurement. MMCAP issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, and contract effectiveness July 1, 2026, requiring vendors to work through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) and maintain cGMP and Drug Supply Chain Security Act compliance. The code shows little activity directly aligned to eletriptan procurement; the recent opportunities reflect broader health-system pharmaceutical sourcing and state procurement cooperative mechanisms.